Yamazaki H, Inoue T, Koizumi M, Yoshida K, Kagawa K, Shiomi H, Nose T, Tanaka E, Teshima T, Nakamura H, Shimizutani K, Furukawa S, Fuchihata H, Inoue T
Department of Radiation Oncology, Osaka University Medical School, Japan.
Anticancer Res. 1997 Jul-Aug;17(4A):2819-22.
The authors report the compatibility of iridium-192 (Ir-192) to Radium-226 (Ra-226) based on the clinical results of three-decades.
From 1967 through 1985, 119 patients with early oral tongue cancer (T1-2N0) were treated with conventional Ra-226 needles and 135 patients with Ir-192 hair pins.
Local control rates at 10 years for T1 and T2 tongue cancer were 79% and 61% for patients treated with Ra-226, 83% and 68% with Ir-192. The 10-year cause-specific survival rates for the T1 and T2 patients with Ra-226 were 76% and 63%, and those with Ir-192 were 77% and 68%, respectively.
Ir-192 showed good possibilities as a substitute for Ra-226 in brachytherapy for early oral tongue cancer.
作者基于三十年的临床结果报告了铱 - 192（Ir - 192）与镭 - 226（Ra - 226）的兼容性。
从1967年到1985年，119例早期口腔舌癌（T1 - 2N0）患者接受了传统的Ra - 226针治疗，135例患者接受了Ir - 192发夹治疗。
对于T1和T2舌癌患者，接受Ra - 226治疗的患者10年局部控制率分别为79%和61%，接受Ir - 192治疗的患者为83%和68%。接受Ra - 226治疗的T1和T2患者的10年特定病因生存率分别为76%和63%，接受Ir - 192治疗的患者分别为77%和68%。
在早期口腔舌癌的近距离放射治疗中，Ir - 192显示出作为Ra - 226替代品的良好可能性。
